BioPharma Pharma Research

Lonza Licenses NeuroPortal Blood-Brain Barrier Technology to China Medical System

Lonza grants CMS global rights to newly acquired TfR1 technology in up to two neurodegenerative disease targets.  Lonza’s NeuroPortal...

 November 18, 2026 | News

Delonix Bioworks and A*STAR IDL Collaborate on Vaccines Against Drug-Resistant Klebsiella pneumoniae

Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has ente...

 November 18, 2026 | News

The 10 New Drugs Japan Expects to Sell Most: Peak-Sales Forecasts From Every 2026 NHI Listing Round

On 13 November, 16 new medicines joined Japan's National Health Insurance (NHI) price list. It was the last of the seven listing rounds Japan now runs each...

 November 18, 2026 | Analysis

Orphalan Expands Phase 3 Wilson Disease Trial to China

Phase 3 trial evaluates the safety and efficacy of an investigational once-daily formulation of trientine tetrahydrochloride compared to D-penicillamine ...

 November 17, 2026 | News

Sanyou Bio Secures Nearly RMB 100 Million in Series C to Advance AI-Driven Drug R&D

Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") rece...

 November 11, 2026 | News

InventisBio’s Nomelcitinib Achieves Over 70% PASI 90 Response in Phase III Psoriasis Trial

InventisBio Co., Ltd.  announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key s...

 November 04, 2026 | News

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

 November 03, 2026 | Regulatory

Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial

Alkermes plc  announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...

 November 02, 2026 | News

Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results

The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements ac...

 November 02, 2026 | News

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

 October 30, 2026 | News

MEPSGEN Launches NanoCalibur Mini to Accelerate Nanoparticle Formulation for Drug Discovery

Automated system enables rapid, reproducible formulation screening with minimal sample consumption Completes the NanoCalibur® Series (Mini, Lab, Pro...

 October 28, 2026 | News

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

 October 27, 2026 | News

Insilico Medicine Hits First AI-Driven Oncology Milestone in $888 Million Servier Collaboration

Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reach...

 October 22, 2026 | News

The PD-(L)1 x VEGF Bispecific Race: Every APAC Programme in the Clinic, Counted

When the ESMO Congress opens in Madrid on 23 October, one drug class will be hard to miss. Two days in, on the evening of Sunday 25 October, the Presidenti...

 October 16, 2026 | Analysis


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close